Seminal vesicles

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

NurExone’s Intellectual Property Portfolio Expands

Retrieved on: 
Tuesday, February 20, 2024

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.
  • NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves.
  • The loading technology was presented to the public in the press release of February 12, 2024.
  • Aspects of the company’s platform which relate to Extracellular Vesicles (EVs) production are described in a growing intellectual property portfolio with two PCT applications currently in National Phases.

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Retrieved on: 
Tuesday, March 5, 2024

The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.

Key Points: 
  • The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.
  • “These results provide further evidence that the APEX platform has the potential to offer highly sensitive and accurate Alzheimer’s disease diagnosis equivalent to PET scans from a simple blood draw,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • The APEX Aβ test is a blood-based diagnostic that uniquely detects very low levels of disease-specific proteins in blood with high accuracy.
  • EV-associated Aβ in blood are highly correlative and a direct reflection of Aβ build-up in the brain, a key abnormality in Alzheimer’s disease.

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

IMCAS 2024: Rion Aesthetics’ CEO, Alisa Lask, to Unveil Cutting-Edge Platelet-Derived Exosome Technology Insights

Retrieved on: 
Thursday, February 1, 2024

Rion Aesthetics, a trailblazer in regenerative aesthetics, announced today that its internationally-recognized CEO, Alisa Lask, will present at the illustrious International Master Course on Aging Science (IMCAS) meeting in Paris.

Key Points: 
  • Rion Aesthetics, a trailblazer in regenerative aesthetics, announced today that its internationally-recognized CEO, Alisa Lask, will present at the illustrious International Master Course on Aging Science (IMCAS) meeting in Paris.
  • View the full release here: https://www.businesswire.com/news/home/20240201151491/en/
    Alisa Lask, CEO of Rion Aesthetics, with a diverse background in medical devices, pharmaceuticals, and skincare markets, stands at the forefront of revolutionizing the regenerative aesthetics industry.
  • (Photo: Business Wire)
    We stand at a pivotal moment in the evolution of regenerative aesthetics," said Alisa Lask.
  • Leading this transformative movement is Alisa Lask, whose expertise and vision at Rion Aesthetics have been critical in exploring the potential of exosomes.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Retrieved on: 
Monday, January 8, 2024

Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.

Key Points: 
  • Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.
  • PluriCDMO™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector.
  • HAIFA, Israel, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO™.
  • Its state-of-the-art 47 thousand square foot Good Manufacturing Practice (GMP) cell therapy production facility is expected to help customers and partners address key challenges in the development and manufacturing of cell-based therapies.

ECM Therapeutics Announces Collaboration with the Louis J. Fox Center at the University of Pittsburgh Vision Institute to Advance Cutting-edge Technology for Optic Nerve Repair

Retrieved on: 
Tuesday, December 19, 2023

Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine .

Key Points: 
  • Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine .
  • MBV are a distinct class of extracellular vesicles embedded within the extracellular matrix (ECM) that are enriched in pro-resolving lipids, anti-inflammatory protein and miRNA cargo.
  • The combined resources of the two entities will address the formidable challenge of restoring vision following optic nerve damage.
  • For more information on ECM Therapeutics, please visit www.ecmtherapeutics.com or follow the company on LinkedIn .